Inhibition of Skin Pathogenic Bacteria, Antioxidant and Anti-Inflammatory Activity of Royal Jelly from Northern Thailand.
| Title: | Inhibition of Skin Pathogenic Bacteria, Antioxidant and Anti-Inflammatory Activity of Royal Jelly from Northern Thailand. |
|---|---|
| Authors: | Uthaibutra V; Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.; Master of Science Program in Applied Microbiology (International Program), Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.; Graduate School, Chiang Mai University, Chiang Mai 50200, Thailand.; Kaewkod T; Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.; Prapawilai P; Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.; Pandith H; Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.; Tragoolpua Y; Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.; Center of Excellence in Materials Science and Technology, Chiang Mai University, Chiang Mai 50200, Thailand.; Research Center in Bioresource for Agriculture, Industry, and Medicine, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand. |
| Source: | Molecules (Basel, Switzerland) [Molecules] 2023 Jan 19; Vol. 28 (3). Date of Electronic Publication: 2023 Jan 19. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI, c1995- |
| MeSH Terms: | Antioxidants*/pharmacology ; Methicillin-Resistant Staphylococcus aureus*/metabolism; Anti-Bacterial Agents/pharmacology ; Anti-Inflammatory Agents/pharmacology ; Fatty Acids/pharmacology ; Fatty Acids/metabolism ; Animals ; Bees ; Staphylococcus aureus ; Thailand ; Skin ; Mice ; Cell Line ; Royal Jelly |
| Abstract: | Royal jelly is a nutritious substance produced by the hypopharyngeal and mandibular glands of honeybees. Royal jelly possesses many attractive and beneficial properties which make it an ideal component in medical and pharmaceutical products. The antibacterial, antioxidant, and anti-inflammatory activities of royal jelly from honeybees (Apis mellifera) were determined in this study. Moreover, the total phenolic and flavonoid contents of the royal jelly were also evaluated. The effects of royal jelly on growth inhibition against skin pathogenic bacteria, including Cutibacterium acnes, methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, and Corynebacterium spp., were investigated by the agar well diffusion method. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were further determined by the broth dilution method. The results indicated that royal jelly showed antibacterial activity by inhibiting the growth of Gram-positive pathogenic bacteria, while the effectiveness decreased against Gram-negative bacteria. Interestingly, royal jelly from Lamphun (RJ-LP1), and Chiang Mai (RJ-CM1), presented high inhibitory efficacy against C. acnes, MRSA, and S. aureus within 4 h by a time killing assay. Furthermore, the anti-inflammatory properties of royal jelly were tested using RAW264.7 macrophage cells, and results revealed that RJ-LP1 and RJ-CM1 could reduce nitric oxide (NO) production and suppress iNOS gene expression. After testing the antioxidant activity, RJ-CM1 and RJ-CM2 of royal jelly from Chiang Mai had the highest level. Additionally, RJ-CM1 also showed the highest total phenolic and flavonoid content. These findings have brought forward new knowledge of the antibacterial, antioxidant, and anti-inflammatory properties of royal jelly, which will improve clinical and pharmaceutical uses of royal jelly as an alternative therapy for bacterial infections, and also as a dietary supplement product. |
| References: | Biomed Res Int. 2015;2015:239519. (PMID: 26247012); J Agric Food Chem. 2006 Oct 18;54(21):8328-34. (PMID: 17032047); Nat Rev Immunol. 2014 May;14(5):289-301. (PMID: 24722477); FEBS Lett. 2002 Sep 25;528(1-3):125-9. (PMID: 12297291); Exp Gerontol. 2003 Sep;38(9):965-9. (PMID: 12954483); BMC Genomics. 2019 Nov 6;20(1):815. (PMID: 31694542); J Proteome Res. 2013 Jan 4;12(1):404-11. (PMID: 23157659); Biomed Res. 2013 Aug;34(4):205-14. (PMID: 23995057); J Pharm Biomed Anal. 2006 Jun 16;41(4):1220-34. (PMID: 16621403); Int J Mol Sci. 2018 Feb 03;19(2):. (PMID: 29401674); Science. 2009 May 29;324(5931):1190-2. (PMID: 19478181); Int Immunopharmacol. 2005 Apr;5(4):679-88. (PMID: 15710337); Chemosphere. 2014 Aug;108:197-204. (PMID: 24530163); Evid Based Complement Alternat Med. 2017;2017:4534350. (PMID: 29234399); Evid Based Complement Alternat Med. 2019 Nov 30;2019:3715481. (PMID: 31871479); J Agric Food Chem. 2008 Dec 10;56(23):11447-52. (PMID: 19007163); Peptides. 2015 Jun;68:190-6. (PMID: 25784287); Clin Microbiol Infect. 2004 Jan;10(1):12-26. (PMID: 14706082); BMC Complement Altern Med. 2010 Jun 23;10:30. (PMID: 20573205); Immunology. 2017 Jan;150(1):1-6. (PMID: 27311879); Microbiol Res. 2016 Nov;192:130-141. (PMID: 27664731); Genome Med. 2012 Oct 10;4(10):77. (PMID: 23050952); J Pharm Anal. 2016 Apr;6(2):71-79. (PMID: 29403965); Eur Biophys J. 2011 Apr;40(4):387-97. (PMID: 21336522); Curr Opin Pharmacol. 2007 Aug;7(4):412-7. (PMID: 17627887); J Ethnopharmacol. 2001 Feb;74(2):105-12. (PMID: 11167028); Mediators Inflamm. 2016;2016:3583684. (PMID: 27847405); Nutrients. 2022 Aug 30;14(17):. (PMID: 36079835); J Antimicrob Chemother. 2008 Aug;62(2):256-78. (PMID: 18474513); Biosci Biotechnol Biochem. 2004 Jan;68(1):138-45. (PMID: 14745176); J Investig Dermatol Symp Proc. 2001 Dec;6(3):170-4. (PMID: 11924823); PLoS One. 2015 Apr 01;10(4):e0120238. (PMID: 25830314); BMC Complement Med Ther. 2020 Nov 23;20(1):357. (PMID: 33225942); Nat Rev Immunol. 2004 Jul;4(7):499-511. (PMID: 15229469); BMC Complement Altern Med. 2014 Sep 03;14:330. (PMID: 25182043); Oxid Med Cell Longev. 2017;2017:1259510. (PMID: 28814983); ScientificWorldJournal. 2018 Dec 18;2018:8429809. (PMID: 30662377); J Evid Based Complementary Altern Med. 2016 Oct;21(4):NP43-8. (PMID: 26620573) |
| Grant Information: | NRCT5-RRI63004-M09 National Research Council of Thailand |
| Contributed Indexing: | Keywords: anti-inflammatory; antibacterial activity; antioxidant activity; royal jelly; skin pathogenic bacteria |
| Substance Nomenclature: | 0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Fatty Acids); L497I37F0C (Royal Jelly) |
| Entry Date(s): | Date Created: 20230211 Date Completed: 20230222 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9920569 |
| DOI: | 10.3390/molecules28030996 |
| PMID: | 36770665 |
| Database: | MEDLINE |
Journal Article